Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Harp

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Neuroimmunology|July 28, 2009
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosisElizabeth M Cameron, Sade Spencer, Jonathan Lazarini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 9, 2011
Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cellsDaniel R Getts, Danielle M Turley, Cassandra E Smith, et al.
Science Advances|January 2, 2026
STING/type I interferon pathway is required for antigen-containing PLGA nanoparticle- and apoptotic cell-induced CD4+ T cell toleranceJoseph R Podojil, Andrew C Cogswell, Tobias Neef, et al.
Plos One|March 2, 2011
Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitisNancy L Monson, Petra Cravens, Rehana Hussain, et al.
European Journal of Immunology|September 3, 2010
Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoproteinChristopher T Harp, Sara Ireland, Laurie S Davis, et al.
The Lancet. Neurology|July 19, 2025
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension studyAmit Bar-Or, Michal Dufek, Hrvoje Budincevic, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2023
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activityKoji Shinoda, Rui Li, Ayman Rezk, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Neuroimmunology|July 28, 2009
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosisElizabeth M Cameron, Sade Spencer, Jonathan Lazarini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 9, 2011
Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cellsDaniel R Getts, Danielle M Turley, Cassandra E Smith, et al.
Science Advances|January 2, 2026
STING/type I interferon pathway is required for antigen-containing PLGA nanoparticle- and apoptotic cell-induced CD4+ T cell toleranceJoseph R Podojil, Andrew C Cogswell, Tobias Neef, et al.
Plos One|March 2, 2011
Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitisNancy L Monson, Petra Cravens, Rehana Hussain, et al.
European Journal of Immunology|September 3, 2010
Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoproteinChristopher T Harp, Sara Ireland, Laurie S Davis, et al.
The Lancet. Neurology|July 19, 2025
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension studyAmit Bar-Or, Michal Dufek, Hrvoje Budincevic, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2023
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activityKoji Shinoda, Rui Li, Ayman Rezk, et al.
Pageof 2